[	0	1	O
Clinical	1	9	O
significance	10	22	O
of	23	25	O
interleukin	26	37	B-Gene_or_gene_product
-	37	38	I-Gene_or_gene_product
6	38	39	I-Gene_or_gene_product
(	40	41	O
IL	41	43	B-Gene_or_gene_product
-	43	44	I-Gene_or_gene_product
6	44	45	I-Gene_or_gene_product
)	45	46	O
as	47	49	O
a	50	51	O
prognostic	52	62	O
factor	63	69	O
of	70	72	O
cancer	73	79	B-Pathological_formation
disease	80	87	O
]	87	88	O

Interleukin	90	101	B-Gene_or_gene_product
-	101	102	I-Gene_or_gene_product
6	102	103	I-Gene_or_gene_product
(	104	105	O
IL	105	107	B-Gene_or_gene_product
-	107	108	I-Gene_or_gene_product
6	108	109	I-Gene_or_gene_product
)	109	110	O
is	111	113	O
proinflammatory	114	129	O
cytokine	130	138	O
that	139	143	O
produces	144	152	O
multifunctional	153	168	O
effects	169	176	O
.	176	177	O

It	178	180	O
is	181	183	O
also	184	188	O
involved	189	197	O
in	198	200	O
the	201	204	O
regulation	205	215	O
of	216	218	O
immune	219	225	O
reactions	226	235	O
,	235	236	O
hematopoiesis	237	250	O
and	251	254	O
inflammatory	255	267	O
state	268	273	O
.	273	274	O

Interleukin	275	286	B-Gene_or_gene_product
-	286	287	I-Gene_or_gene_product
6	287	288	I-Gene_or_gene_product
has	289	292	O
been	293	297	O
shown	298	303	O
to	304	306	O
be	307	309	O
associated	310	320	O
with	321	325	O
tumor	326	331	B-Pathological_formation
progression	332	343	O
including	344	353	O
inhibition	354	364	O
of	365	367	O
cancer	368	374	B-Cell
cells	375	380	I-Cell
apoptosis	381	390	O
and	391	394	O
stimulation	395	406	O
of	407	409	O
angiogenesis	410	422	O
.	422	423	O

Anti	424	428	O
-	428	429	O
IL	429	431	B-Gene_or_gene_product
-	431	432	I-Gene_or_gene_product
6	432	433	I-Gene_or_gene_product
therapy	434	441	O
is	442	444	O
a	445	446	O
new	447	450	O
strategy	451	459	O
in	460	462	O
the	463	466	O
inflammatory	467	479	O
autoimmune	480	490	O
diseases	491	499	O
and	500	503	O
cancer	504	510	B-Pathological_formation
.	510	511	O

Clinical	512	520	O
studies	521	528	O
have	529	533	O
shown	534	539	O
elevated	540	548	O
serum	549	554	B-Organism_substance
IL	555	557	B-Gene_or_gene_product
-	557	558	I-Gene_or_gene_product
6	558	559	I-Gene_or_gene_product
concentrations	560	574	O
in	575	577	O
patients	578	586	B-Organism
with	587	591	O
endometrial	592	603	B-Pathological_formation
cancer	604	610	I-Pathological_formation
,	610	611	O
non	612	615	B-Pathological_formation
-	615	616	I-Pathological_formation
small	616	621	I-Pathological_formation
cell	622	626	I-Pathological_formation
lung	627	631	I-Pathological_formation
carcinoma	632	641	I-Pathological_formation
,	641	642	O
colorectal	643	653	B-Pathological_formation
cancer	654	660	I-Pathological_formation
,	660	661	O
renal	662	667	B-Pathological_formation
cell	668	672	I-Pathological_formation
carcinoma	673	682	I-Pathological_formation
,	682	683	O
breast	684	690	B-Pathological_formation
and	691	694	O
ovarian	695	702	B-Pathological_formation
cancer	703	709	I-Pathological_formation
.	709	710	O

Serum	711	716	B-Organism_substance
IL	717	719	B-Gene_or_gene_product
-	719	720	I-Gene_or_gene_product
6	720	721	I-Gene_or_gene_product
levels	722	728	O
correlate	729	738	O
with	739	743	O
tumor	744	749	B-Pathological_formation
stage	750	755	O
,	755	756	O
and	757	760	O
survival	761	769	O
of	770	772	O
patients	773	781	B-Organism
.	781	782	O

In	783	785	O
this	786	790	O
article	791	798	O
we	799	801	O
have	802	806	O
focused	807	814	O
on	815	817	O
a	818	819	O
role	820	824	O
of	825	827	O
IL	828	830	B-Gene_or_gene_product
-	830	831	I-Gene_or_gene_product
6	831	832	I-Gene_or_gene_product
as	833	835	O
a	836	837	O
prognostic	838	848	O
factor	849	855	O
in	856	858	O
several	859	866	O
malignancies	867	879	O
such	880	884	O
as	885	887	O
colorectal	888	898	B-Pathological_formation
cancer	899	905	I-Pathological_formation
,	905	906	O
breast	907	913	B-Pathological_formation
cancer	914	920	I-Pathological_formation
,	920	921	O
gastric	922	929	B-Pathological_formation
cancer	930	936	I-Pathological_formation
and	937	940	O
pancreatic	941	951	B-Pathological_formation
cancer	952	958	I-Pathological_formation
.	958	959	O

